Ann Robbins, PhD
Dr. Robbins is an accomplished regulatory affairs professional with over 25 years of experience providing regulatory leadership and strategic advice to large pharmaceutical, small startup companies, and non-profit organizations on global drug development programs, with special expertise in neuroscience and women’s health products. She received her PhD in Neuroscience from Florida State University, followed by a post-doctoral fellowship in the Laboratory of Neurobiology and Behavior at Rockefeller University.
At C-Path, Robbins provides regulatory advice and strategy across a variety of overarching projects at C-Path including chairing the committee that reviews all C-Path regulatory documents prior to submission to regulatory authorities, fostering regulatory learnings, particularly on the Drug Development Tool (DDT) qualification process, and preparing and updating best regulatory practice guidelines for the organization. In addition, Dr. Robbins serves in regulatory leadership roles in the Critical Path to TB Regimens (CPTR) intiative and the Multiple Sclerosis Outcome Assessments Consortium (MSOAC), with a focus on DDT qualification of biomarkers and clinical outcome assessment tools.